Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302

Biological Trace Element Research

Volumn 136, Issue 3, 2010, Pages 294-301

  Li, Shengrong ^a   Zhang, Jinsong ^b   Li, Jun ^c   Chen, Dongming ^a   Matteucci, Mark ^d   Curd, John ^d   Duan, Jian Xin ^d  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI AGRICULTURAL UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d Threshold Pharmaceuticals   (United States)

Author keywords

Cancer; Glutathione reductase; TH 302; Thioredoxin reductase

Indexed keywords

2 NITROIMIDAZOLE; ANTINEOPLASTIC AGENT; BROMO ISOPHOSPHORAMIDE; CHLORO ISOPHOSPHORAMIDE; DIPEPTIDE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; IFOSFAMIDE; IMIDAZOLE DERIVATIVE; OXYGEN; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; SELENIUM; SELENOCYSTEINE; TH 302; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES HEPATOMA; CANCER TRANSPLANTATION; CONTROLLED STUDY; COVALENT BOND; DNA ALKYLATION; DRUG ACTIVATION; DRUG CONJUGATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HYPOXIA; MALE; MOUSE; NONHUMAN; REDUCTION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME ASSAYS; GLUTATHIONE REDUCTASE; INJECTIONS, INTRAPERITONEAL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MOLECULAR STRUCTURE; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; THIOREDOXIN-DISULFIDE REDUCTASE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

MUS;

EID: 77955551373     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12011-009-8544-1     Document Type: Article

References (20)

1. ES Arnér A Holmgren 2000 Physiological functions of thioredoxin and thioredoxin reductase Eur J Biochem 267 6102 6109 10.1046/j.1432-1327.2000. 01701.x 11012661
2. S Gromer S Urig K Becker 2004 The thioredoxin system from science to clinic Med Res Rev 24 40 89 10.1002/med.10051 1:CAS:528:DC%2BD2cXltVaiug%3D%3D 14595672 (Pubitemid 38018595)
3. VN Gladyshev KT Jeang TC Stadtman 1996 Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene Proc Natl Acad Sci USA 93 6146 6151 10.1073/pnas.93.12.6146 1:CAS:528:DyaK28Xjs1Ojt7c%3D 8650234 (Pubitemid 26190818)
4. S Gromer L Johansson H Bauer, et al. 2003 Active sites of thioredoxin reductases: why selenoproteins? Proc Natl Acad Sci USA 100 12618 12623 10.1073/pnas.2134510100 1:CAS:528:DC%2BD3sXoslKntro%3D 14569031 (Pubitemid 37339948)
5. G Powis D Mustacich A Coon 2000 The role of the redox protein thioredoxin in cell growth and cancer Free Radical Biol Med 29 311 322 10.1016/S0891- 5849(00)00313-0
6. P Nguyen RT Awwad DDK Smart, et al. 2006 Thioredoxin reductase as a novel molecular target for cancer therapy Cancer Lett 236 164 174 10.1016/j.canlet.2005.04.028 1:CAS:528:DC%2BD28XkvVynurc%3D 15955621 (Pubitemid 44262309)
7. T Tamura TC Stadtman 1996 A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity Proc Natl Acad Sci USA 93 1006 1011 10.1073/pnas.93.3.1006 1:CAS:528:DyaK28Xptl2nsw%3D%3D 8577704 (Pubitemid 26054364)
8. MH Yoo XM Xu BA Carlson, et al. 2006 Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells J Biol Chem 281 13005 13008 10.1074/jbc.C600012200 1:CAS:528:DC%2BD28Xkt1ynu7k%3D 16565519 (Pubitemid 43855208)
9. J Lu E Chew Holmgren 2007 Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide Proc Natl Acad Sci USA 104 12288 12293 10.1073/pnas.0701549104 1:CAS:528:DC%2BD2sXos1ehsbw%3D 17640917 (Pubitemid 47206130)
10. J Duan H Jiao J Kaizerman T Stanton, et al. 2008 Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs J Med Chem 51 2412 2420 10.1021/jm701028q 1:CAS:528:DC%2BD1cXhslWis7s%3D 18257544 (Pubitemid 351628502)
11. J Zhang H Lu 2007 Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity Free Radical Biol Med 43 1574 1583 10.1016/j.freeradbiomed.2007.08.020 1:CAS:528:DC%2BD2sXhtlGnsrnL (Pubitemid 350122981)
12. S Gromer RH Schirmer K Becker 1997 The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase FEBS Lett 412 318 320 10.1016/S0014- 5793(97)00816-8 1:CAS:528:DyaK2sXks12ltr0%3D 9256243 (Pubitemid 27321274)
13. KE Hill GW McCollum RF Burk 1997 Determination of thioredoxin reductase activity in rat liver supernatant Anal Biochem 253 123 125 10.1006/abio.1997. 2373 1:CAS:528:DyaK2sXnsVegt74%3D 9356150 (Pubitemid 27490613)
14. I Carlberg B Mannervik 1985 Glutathione reductase Methods Enzymol 113 484 490 10.1016/S0076-6879(85)13062-4 1:CAS:528:DyaL28XkslCqsQ%3D%3D 3003504
15. J Zhang K Ma H Wang 2006 Cyclophosphamide suppresses thioredoxin reductase in bladder tissue and its adaptive response via inductions of thioredoxin reductase and glutathione peroxidase Chem-Biol Interact 162 24 30 10.1016/j.cbi.2006.04.008 1:CAS:528:DC%2BD28XntlWgtLw%3D 16797508 (Pubitemid 44088653)
16. J Zhang X Wang H Lu 2008 Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase Cancer Lett 260 127 136 10.1016/j.canlet.2007.10.023 1:CAS:528: DC%2BD1cXosFaruw%3D%3D 18039557
17. Y Zhao T Seefeldt 2009 Effects of glutathione reductase inhibition on cellular thiol redox state and related systems Arch Biochem Biophys 485 56 62 10.1016/j.abb.2009.03.001 1:CAS:528:DC%2BD1MXkslyjtrw%3D 19272349
18. SM Kanzok A Fechner H Bauer, et al. 2001 Substitution of the thioredoxin system for glutathione reductase in Drosophila melanogaster Science 291 643 646 10.1126/science.291.5504.643 1:CAS:528:DC%2BD3MXntlWksg%3D%3D 11158675 (Pubitemid 32150421)
19. R Ozols KG Louie J Plowman 1987 Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione Biochem Pharmacol 36 147 153 10.1016/0006-2952(87) 90392-3 1:CAS:528:DyaL2sXhsV2jsbo%3D 3801051 (Pubitemid 17227223)
20. H Maeda S Hori H Ohizumi, et al. 2004 Effective treatment of advanced solid tumors by the combination of arsenic trioxide and l-buthionine-sulfoximine Cell Death Differ 11 737 746 10.1038/sj.cdd.4401389 1:CAS:528: DC%2BD2cXkvFWmsrw%3D 15002036 (Pubitemid 39023120)